<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04011254</url>
  </required_header>
  <id_info>
    <org_study_id>19HH5153</org_study_id>
    <nct_id>NCT04011254</nct_id>
  </id_info>
  <brief_title>Haemodialysis fMRI Salt Appetite Study</brief_title>
  <acronym>HeMSA</acronym>
  <official_title>Examining Salt Appetite in Haemodialysis Patients Using Functional Magnetic Resonance Imaging</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Forschungszentrum Juelich</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Imperial College London</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. Assessing how the rapid removal of salt and water by haemodialysis alters regional brain&#xD;
           activity (by measurement of the brain blood oxygen level-dependent (BOLD) signal using&#xD;
           functional MRI) during tasting of soup of differing salt concentrations.&#xD;
&#xD;
        2. Identify differences in the brain response to salt taste pre- and post-haemodialysis&#xD;
           between haemodialysis patients who are either able or unable to control between dialysis&#xD;
           weight gain&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      HeMSA Study Phase 2 Up to 20 male, haemodialysis patient who have average %IDWG &gt;4% will be&#xD;
      recruited with the target, to proceed to scanning, of 14 patients. Following consent the&#xD;
      patients will complete questionnaires (including Salt intake questionnaire - DSQ (Gkza and&#xD;
      Davenport, 2017), Edinburgh handedness questionnaire (Oldfield, 1971), MRI checklist) and&#xD;
      undergo salt taste preference and threshold testing during a 1 hour session prior to&#xD;
      dialysis. The purpose of this visit is to establish the tasteless solution and 2 soup salt&#xD;
      concentrations to be used in the salt taste fMRI paradigm, obtain baseline data regarding&#xD;
      estimate of salt intake and ensure MRI is safe for this patient.&#xD;
&#xD;
      Patients will then attend 2 MRI scanning visits at the Hammersmith Hospital Imperial Campus,&#xD;
      one the morning immediately before haemodialysis and one the morning after haemodialysis.&#xD;
      Prior to the MRI session, at the Imperial College Clinical Research Facility, the patient&#xD;
      will undergo various clinical assessments and have venous blood samples taken. The MRI will&#xD;
      be undertaken at the Imperial College Clinical Imaging Facility using a Siemens 3T Verio&#xD;
      scanner. During the scan subjects will taste, via a taste delivery system, aliquots of&#xD;
      tasteless solution, sucralose, and 2 soup with different concentrations of salt. Solutions&#xD;
      will be delivered in a block design.&#xD;
&#xD;
      HeMSA Study Phase 3 3 groups (healthy controls, haemodialysis (HD) patients with %IDWG &lt;4%,&#xD;
      haemodialysis patients with %IDWG &gt;4% - patients froms phase 2 will contribute to the latter&#xD;
      group) Protocol will follow that for HeMSA Phase 2. Healthy controls will also have 2 study&#xD;
      visits at a similar period apart to the HD participants.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 17, 2020</start_date>
  <completion_date type="Anticipated">November 2024</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in regional brain BOLD signal during tasting of soup of differing salt concentrations (vs. artificial saliva) pre dialysis session verse post dialysis session</measure>
    <time_frame>1 week (maximal time between pre and post dialysis scan)</time_frame>
    <description>Regional brain BOLD signal during tasting of soup of differing salt concentrations (vs. artificial saliva) ROI including insula, amygdala, ventral tegmental area, pre frontal cortex,</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in ratings of salt liking and intensity across different salt concentrations of soup</measure>
    <time_frame>1 week (maximal time between pre and post dialysis scan)</time_frame>
    <description>Ratings of liking, via Labelled Hedonic Scale (LHS) (-100=Most disliked sensation imaginable, 0=neural, 100=Most liked sensation imaginable), of salted soup of 2 concentrations pre dialysis session verse post dialysis session</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ratings of sweet liking and intensity pre dialysis session verse post dialysis session</measure>
    <time_frame>1 week (maximal time between pre and post dialysis scan)</time_frame>
    <description>Ratings of liking and intensity, via Labelled Hedonic Scale (LHS) (-100=Most disliked sensation imaginable, 0=neural, 100=Most liked sensation imaginable), of sucralose solution</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratings of sour liking and intensity</measure>
    <time_frame>1 week (maximal time between pre and post dialysis scan)</time_frame>
    <description>Rating of liking and intensity, via Labelled Hedonic Scale (LHS) (-100=Most disliked sensation imaginable, 0=neural, 100=Most liked sensation imaginable) of citrate pre dialysis session verse post dialysis session</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Salt threshold testing</measure>
    <time_frame>1 week (maximal time between pre and post dialysis scan)</time_frame>
    <description>The lowest concentration of saline solution detected by taste. pre dialysis session verse post dialysis session</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arterial spin labelling</measure>
    <time_frame>1 week (maximal time between pre and post dialysis scan)</time_frame>
    <description>arterial spin labelling measurement of regional cerebral blood flow at rest pre dialysis session verse post dialysis session</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cerebral vascular reactivity pre dialysis session verse post dialysis session</measure>
    <time_frame>1 week (maximal time between pre and post dialysis scan)</time_frame>
    <description>BOLD signal changes during breath hold to assess BOLD signal reactivity to increased CO2 concentrations</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Dialysis</condition>
  <condition>Excess Interdialytic Weight Gain</condition>
  <arm_group>
    <arm_group_label>Healthy Control</arm_group_label>
    <description>Healthy control</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Haemodialysis %IDWG &gt;4%</arm_group_label>
    <description>Patient on regular haemodialysis with average IDWG &gt;4%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Haemodialysis %IDWG &lt;4%</arm_group_label>
    <description>Patient on regular haemodialysis with average IDWG &lt;4%</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>haemodialysis</intervention_name>
    <description>Routine haemodialysis session</description>
    <arm_group_label>Haemodialysis %IDWG &lt;4%</arm_group_label>
    <arm_group_label>Haemodialysis %IDWG &gt;4%</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      venous blood&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Haemodialysis patients under the care of Imperial College NHS Healthcare Trust and healthy&#xD;
        controls&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        All participants:&#xD;
&#xD;
          -  Male&#xD;
&#xD;
          -  Aged 18-65 years&#xD;
&#xD;
          -  Non-smoker (ex-smokers allowed)&#xD;
&#xD;
          -  Right handed (able to use a right handed response button)&#xD;
&#xD;
          -  Able to tolerate 1 hour MRI scanning session&#xD;
&#xD;
        For haemodialysis patients:&#xD;
&#xD;
          -  Established on haemodialysis for more than 6 months&#xD;
&#xD;
          -  Urine output &lt;200ml/24 hours&#xD;
&#xD;
          -  Average (over the past month) interdialytic weight gain:&#xD;
&#xD;
               1. Main phase 2: &gt;4 %IDWG&#xD;
&#xD;
               2. Main phase 3: &lt;4 or &gt;4 %IDWG&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Type 1 or type 2 diabetes mellitus&#xD;
&#xD;
          -  Current smoker&#xD;
&#xD;
          -  Uncontrolled depression (change in use of anti-depressants in last 3 months, or BDI-II&#xD;
             score &gt;28/63)&#xD;
&#xD;
          -  Neurological disorder (Parkinson's disease, serious cerebrovascular disease, epilepsy,&#xD;
             moderate-severe traumatic brain injury, dementia)&#xD;
&#xD;
          -  Previous bariatric surgery&#xD;
&#xD;
          -  Inflammatory state (CRP &gt;20 on routine dialysis blood tests)&#xD;
&#xD;
          -  Acute infective illness&#xD;
&#xD;
          -  Significant current or past medical or psychiatric history, or use of medications,&#xD;
             that, in the opinion of the Investigators, contraindicates their participation, due to&#xD;
             influence on outcome measures.&#xD;
&#xD;
          -  Patients lacking capacity or unable to consent and non-English language speakers&#xD;
&#xD;
          -  Contra-indication to MRI imaging e.g. metal insert, pacemaker&#xD;
&#xD;
          -  Claustrophobia&#xD;
&#xD;
          -  Patients currently participating in an active CTIMP trial, or within 4 half-lives of&#xD;
             last administration of CTIMP product&#xD;
&#xD;
          -  Serious mental illness (e.g. bipolar disorder, schizophrenia)&#xD;
&#xD;
          -  Current alcohol or drug dependence&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eleanor C Sandhu, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Imperial College London</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tony Goldstone, BM ChB</last_name>
    <role>Study Director</role>
    <affiliation>Imperial College London</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eleanor C Sandhu, MBBS</last_name>
    <phone>02033133980</phone>
    <email>eleanor.sandhu@nhs.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tony Goldstone, BM ChB</last_name>
    <phone>02075945989</phone>
    <email>tony.goldstone@imperial.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Imperial College Healthcare NHS Trust</name>
      <address>
        <city>London</city>
        <zip>W12 0NN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eleanor C Sandhu, MBBS</last_name>
      <phone>020331333980</phone>
      <email>eleanor.sandhu@ic.ac.uk</email>
    </contact>
    <contact_backup>
      <last_name>Tony Goldstone, BM ChB</last_name>
      <phone>020 7594 5989</phone>
      <email>tony.goldstone@imperial.ac.uk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>June 25, 2019</study_first_submitted>
  <study_first_submitted_qc>July 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 8, 2019</study_first_posted>
  <last_update_submitted>September 11, 2020</last_update_submitted>
  <last_update_submitted_qc>September 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>salt taste preference</keyword>
  <keyword>salt taste sensitivity</keyword>
  <keyword>functional Magnetic Resonance Imaging</keyword>
  <keyword>Dialysis</keyword>
  <keyword>Salt taste</keyword>
  <keyword>salt intake</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Weight Gain</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

